Matches in DBpedia 2016-04 for { ?s ?p "AB-FUBINACA is a drug that acts as a potent agonist for the cannabinoid receptors, with Ki values of 0.9 nM at CB1 and 23.2 nM at CB2, and EC50 values of 1.8 nM at CB1 and 3.2 nM at CB2. It was originally developed by Pfizer in 2009 as an analgesic medication, but was never pursued for human use. Subsequently in 2012, this compound was discovered as an ingredient in synthetic cannabis blends in Japan, along with a related compound AB-PINACA which had not previously been reported."@en }
Showing triples 1 to 4 of
4
with 100 triples per page.
- AB-FUBINACA abstract "AB-FUBINACA is a drug that acts as a potent agonist for the cannabinoid receptors, with Ki values of 0.9 nM at CB1 and 23.2 nM at CB2, and EC50 values of 1.8 nM at CB1 and 3.2 nM at CB2. It was originally developed by Pfizer in 2009 as an analgesic medication, but was never pursued for human use. Subsequently in 2012, this compound was discovered as an ingredient in synthetic cannabis blends in Japan, along with a related compound AB-PINACA which had not previously been reported.".
- Q4650002 abstract "AB-FUBINACA is a drug that acts as a potent agonist for the cannabinoid receptors, with Ki values of 0.9 nM at CB1 and 23.2 nM at CB2, and EC50 values of 1.8 nM at CB1 and 3.2 nM at CB2. It was originally developed by Pfizer in 2009 as an analgesic medication, but was never pursued for human use. Subsequently in 2012, this compound was discovered as an ingredient in synthetic cannabis blends in Japan, along with a related compound AB-PINACA which had not previously been reported.".
- AB-FUBINACA comment "AB-FUBINACA is a drug that acts as a potent agonist for the cannabinoid receptors, with Ki values of 0.9 nM at CB1 and 23.2 nM at CB2, and EC50 values of 1.8 nM at CB1 and 3.2 nM at CB2. It was originally developed by Pfizer in 2009 as an analgesic medication, but was never pursued for human use. Subsequently in 2012, this compound was discovered as an ingredient in synthetic cannabis blends in Japan, along with a related compound AB-PINACA which had not previously been reported.".
- Q4650002 comment "AB-FUBINACA is a drug that acts as a potent agonist for the cannabinoid receptors, with Ki values of 0.9 nM at CB1 and 23.2 nM at CB2, and EC50 values of 1.8 nM at CB1 and 3.2 nM at CB2. It was originally developed by Pfizer in 2009 as an analgesic medication, but was never pursued for human use. Subsequently in 2012, this compound was discovered as an ingredient in synthetic cannabis blends in Japan, along with a related compound AB-PINACA which had not previously been reported.".